Dyne Therapeutics (NASDAQ:DYN) Downgraded by StockNews.com to Sell

StockNews.com lowered shares of Dyne Therapeutics (NASDAQ:DYN) from a hold rating to a sell rating in a report issued on Monday morning.

A number of other brokerages have also recently issued reports on DYN. Oppenheimer reaffirmed an outperform rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. HC Wainwright reiterated a buy rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. Morgan Stanley raised their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an overweight rating in a report on Wednesday, August 14th. Jefferies Financial Group upped their price target on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a buy rating in a report on Monday, May 20th. Finally, Stifel Nicolaus raised their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a buy rating in a report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Dyne Therapeutics has an average rating of Moderate Buy and an average target price of $51.40.

Dyne Therapeutics Trading Up 1.0 %

Shares of Dyne Therapeutics stock opened at $34.40 on Monday. The firm has a market capitalization of $3.01 billion, a PE ratio of -8.66 and a beta of 1.07. Dyne Therapeutics has a 12 month low of $6.40 and a 12 month high of $47.45. The business’s 50-day moving average price is $41.43 and its 200-day moving average price is $33.43.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.02. As a group, analysts predict that Dyne Therapeutics will post -2.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO John Cox acquired 32,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the transaction, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. In other news, COO Susanna Gatti High sold 10,163 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $35.33, for a total value of $359,058.79. Following the sale, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at approximately $5,256,821.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John Cox purchased 32,000 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the transaction, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. The disclosure for this purchase can be found here. 20.77% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Concurrent Investment Advisors LLC bought a new stake in shares of Dyne Therapeutics in the 1st quarter worth approximately $573,000. Sei Investments Co. purchased a new stake in shares of Dyne Therapeutics in the first quarter worth $693,000. Rafferty Asset Management LLC increased its holdings in shares of Dyne Therapeutics by 17.7% during the fourth quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock valued at $2,182,000 after acquiring an additional 24,632 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of Dyne Therapeutics in the 1st quarter worth about $810,000. Finally, Commodore Capital LP purchased a new position in shares of Dyne Therapeutics in the 4th quarter worth about $11,970,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.